TICKERNERD
Menu
TENXTENXHealthcare · Biotechnology

TENX Stock Forecast: Tenax Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.86
−4.62% on the day

The 10 Wall Street analysts covering Tenax Therapeutics, Inc. hold a median 12-month price target of $5 — +168.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 11 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$69.6M
Ticker Nerd rank
22 / 100
Median analyst target
$5.00
Analysts covering
10
Revenue$0.0
Operating income−$18.8M
Net income−$17.8M
Free cash flow−$14.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.5%
1M
+14.8%
YTD
−84.7%
1Y
−69.7%
From 52W high
−89.8%
From 52W low
+35.3%
$1
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TENX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tenax Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
22 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
79
Revisions
63
Volatility
58
Quality
53
Accruals
49
Issuance
23
Growth
10
Momentum
9
Value
7

Size (79): Smaller than most of the companies we track.

Value (7): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TENX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TENX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26TENXHigh $36.00Median $5.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
6 Buy4 Hold0 Sell
Low $4.00Median $5.00High $36.00

The green dot is the last close — the median target sits +168.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
31 Aug 2026GuggenheimDowngradeNeutral—
11 Aug 2026Canaccord GenuityMaintainsBuy—
11 Aug 2026Canaccord GenuityMaintainsBuy$35 → $4.00
11 Aug 2026Chardan CapitalDowngradeNeutral—
11 Aug 2026Chardan CapitalDowngradeNeutral$27 → $5.00
11 Aug 2026Evercore ISI GroupDowngradeIn-Line—
11 Aug 2026Evercore ISI GroupDowngradeIn-Line$39 → $5.00
11 Aug 2026GuggenheimMaintainsBuy—
11 Aug 2026GuggenheimMaintainsBuy$40 → $4.00
10 Aug 2026William BlairDowngradeMarket Perform—
10 Aug 2026William BlairDowngradeMarket Perform—
31 July 2026Chardan CapitalMaintainsBuy—
31 July 2026Chardan CapitalMaintainsBuy$27
29 July 2026Cantor FitzgeraldReiteratesOverweight—
29 July 2026Cantor FitzgeraldReiteratesOverweight$35
28 July 2026Canaccord GenuityInitiatesBuy—
28 July 2026Canaccord GenuityInitiatesBuy$35
22 July 2026Evercore ISI GroupInitiatesOutperform$39
22 July 2026Evercore ISI GroupInitiatesOutperform—
2 July 2026Chardan CapitalMaintainsBuy$27

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TENX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TENX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Tenax Therapeutics, Inc. returned −69.7% against +17.5% for the S&P 500, dividends included.

TENX vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200250300350Oct 25Jan 26Apr 26Jul 26TENXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TENX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
1
Fundamentals

Tenax Therapeutics, Inc. (TENX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.4×

Cheaper than 69% of US stocks

Price / sales
—
Price / book
0.8×

Cheaper than 77% of US stocks

EV / EBITDA
0.2×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−59.8%

Higher than 19% of US stocks

Return on assets
−37.7%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tenax Therapeutics, Inc. (TENX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tenax Therapeutics, Inc. has a market value of $69.6M and an enterprise value of −$11.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$64.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$46.0M.

  • Shares outstanding: 26.5M.

  • Trailing P/E: 2.4×; forward P/E: −1.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Tenax Therapeutics, Inc. employs 14 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

TENX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TENXTenax Therapeutics, Inc.$69.6M
22
CSBRChampions Oncology, Inc.$70.3M
28
KLRSKalaris Therapeutics, Inc.$70.9M
19
NRXSNeurAxis, Inc.$71.1M
55
APLMApollomics, Inc.$67.6M
16
YARWYarrow Bioscience, Inc.$72.1M
53
RNTXRein Therapeutics, Inc.$67.1M
36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tenax Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TENX news & analysis

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

GlobeNewsWire · 1 Sept 2026neutral

Tenax Therapeutics announced that President and CEO Chris Giordano will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET. The presentation is part of the company's participation in the conference.

Why it matters — Tenax watchers would care because the CEO's presentation at a major healthcare conference offers a public platform where the company may communicate updates and developments to investors and industry participants.

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

GlobeNewsWire · 29 Aug 2026positive

Tenax Therapeutics announced that Phase 3 LEVEL results will be presented in late-breaking scientific sessions at ESC Congress 2026. In patients with a baseline six-minute walk distance below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112).

Why it matters — This phase 3 efficacy data on TNX-103 is a key clinical readout for the company's lead candidate, so Tenax watchers will follow the presentation closely.

Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky

PRNewsWire · 19 Aug 2026negative

Tenax Therapeutics shares fell approximately 84% to 85% after the company disclosed that its Phase 3 LEVEL trial of TNX-103 missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations on behalf of TENX investors who suffered losses.

Why it matters — The failed Phase 3 trial results caused a sharp decline in Tenax's share price and triggered a securities investigation, making this a significant development for TENX investors.

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

Business Wire · 16 Aug 2026negative

SBS Law announced an opportunity for Tenax Therapeutics, Inc. (TENX) investors to join a fraud investigation into the company. The notice was issued via Business Wire, inviting affected investors to participate.

Why it matters — A fraud investigation being pursued by a law firm signals potential legal and reputational concerns for Tenax Therapeutics that shareholders may wish to monitor.

TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)

Business Wire · 14 Aug 2026negative

Tenax Therapeutics disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both primary and key secondary endpoints, causing its share price to drop approximately 84% to 85%. Levi & Korsinsky has notified investors of an investigation into the company.

Why it matters — The failed trial and resulting investigation are significant for TENX watchers because the company's lead drug candidate missed its endpoints, erasing most of the company's shareholder value.

FAQ

Frequently asked questions about TENX stock

What is the TENX stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Tenax Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $4 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TENX stock a buy right now?

Of the 10 analysts covering Tenax Therapeutics, Inc., 6 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tenax Therapeutics, Inc. 22 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TENX?

As at 11 Sept 2026, Tenax Therapeutics, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).

Will TENX stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +168.8% from the last close, and Ticker Nerd's factor model ranks Tenax Therapeutics, Inc. 22 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TENX stock forecast for 2030?

No analyst covering Tenax Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TENX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $36 over the next 12 months.

How has TENX stock performed over the past year?

Tenax Therapeutics, Inc. returned -69.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tenax Therapeutics, Inc. do?

Tenax Therapeutics, Inc. is a development-stage pharmaceutical company focused on cardiopulmonary therapies.

What is the latest news on TENX?

The most recent item we track (GlobeNewsWire, 1 Sept 2026): "Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference". Tenax Therapeutics announced that President and CEO Chris Giordano will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET. The presentation is part of the company's participation in the conference.

Company

About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. is a development-stage pharmaceutical company focused on cardiopulmonary therapies. The company develops treatments for serious cardiovascular and pulmonary conditions, with a primary emphasis on pulmonary hypertension associated with heart failure with preserved ejection fraction. Its pipeline includes levosimendan-based programs, as well as other drug candidates aimed at improving outcomes in heart and lung disease. Tenax Therapeutics concentrates on advancing clinical-stage therapies for patients with high unmet medical needs, making it a specialized player in the pharmaceutical market. Headquartered in Chapel Hill, North Carolina, Tenax Therapeutics operates as a research-driven company centered on novel treatments for complex cardiopulmonary disorders.

CEO Mr. Christopher T. Giordano · 14 employees · United States · https://www.tenaxthera.com